Business context and reporting period
DexCom, Inc. filed this Form 10-K for the fiscal year ended December 31, 2014. The medical-device company primarily develops and sells continuous glucose monitoring (CGM) systems for people with diabetes. Most revenue came from its G4 PLATINUM ambulatory system and disposable sensors.
During 2014, DexCom received U.S. FDA approval for pediatric use and professional use of G4 PLATINUM, and FDA approval for its DexCom SHARE remote-monitoring system. The G4 PLATINUM with Share was approved in January 2015, with U.S. commercialization planned for the first quarter of 2015.
Financial performance and position
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Total revenue | $259.2 million | $160.0 million |
| Product revenue | $257.1 million | $157.1 million |
| Gross profit | $176.3 million | $100.1 million |
| Gross margin | 68.0% | 62.6% |
| Operating expenses | $197.8 million | $129.0 million |
| Operating loss | $(21.5) million | $(28.9) million |
| Net loss | $(22.4) million | $(29.8) million |
| Net loss per share | $(0.30) | $(0.42) |
| Cash from operations | $23.6 million | $2.4 million |
| Cash, cash equivalents and short-term securities | $83.6 million | $54.6 million |
| Working capital | $105.3 million | $61.0 million |
| Long-term debt, including current portion | $4.6 million | $6.8 million |
Total revenue grew approximately 62%, principally from increased G4 PLATINUM system and sensor sales as the installed customer base expanded. Product gross profit benefited from higher volume and a greater mix of the higher-margin G4 PLATINUM system. R&D expense rose to $69.4 million and selling, general and administrative expense to $128.4 million, reflecting product development and commercialization investment. Gross margin percentages are calculated from reported figures.
Fourth-quarter 2014 revenue was $84.3 million, compared with $51.7 million in fourth-quarter 2013. DexCom reported fourth-quarter net income of $1.3 million, versus a $2.6 million net loss in the prior-year quarter; the company remained loss-making for the full year. Operating cash flow included substantial noncash share-based compensation of $50.0 million. Capital expenditures were $16.2 million.
Material changes versus the prior comparable period
- Product revenue increased $100.0 million year over year; total revenue rose from $160.0 million to $259.2 million.
- Gross margin improved to 68.0% from 62.6%, while annual net loss narrowed by $7.4 million.
- R&D and SG&A spending increased by $24.6 million and $44.2 million, respectively, as DexCom invested in development, sales capacity and infrastructure.
- Cash from operations increased to $23.6 million from $2.4 million. Cash and short-term marketable securities rose by $29.0 million.
- Long-term debt declined to $4.6 million from $6.8 million. No amount was drawn on the available $15.0 million revolving credit line.
Outlook, commentary, risks and unusual items
- Management expected continued net losses while expanding commercialization, manufacturing and R&D; it believed available resources and expected operating cash contributions would fund anticipated needs through at least December 31, 2015. The filing does not provide a specific revenue or earnings forecast.
- Key commercial risks include limited Medicare coverage, restrictive private-payor reimbursement requirements, and reliance on the G4 PLATINUM product. Byram and Edgepark accounted for approximately 18% and 11% of 2014 revenue, respectively.
- Manufacturing scale-up and dependence on single-source suppliers could constrain product availability. DexCom also reported an FDA warning letter received in March 2014 concerning administrative deficiencies in medical-device reporting; the FDA was reviewing the company’s response.
- DexCom settled Abbott patent litigation in July 2014 through a royalty-free cross-license and mutual covenants not to sue on specified products through March 31, 2021. A change-of-control provision may require a $25 million continuation fee to the non-acquired party.
- In November 2014, DexCom issued 89,300 shares to former SweetSpot security holders to settle remaining acquisition milestones. It recorded a $0.2 million intangible-asset impairment related to the settlement.
- The company remained subject to operating losses and had an accumulated deficit of $497.8 million. Other risks include regulatory approval, product performance and liability, competition, reimbursement, intellectual property, cybersecurity and potential financing needs.
- Kevin Sayer became CEO effective January 1, 2015; former CEO Terrance Gregg became Executive Chairman. Management and the independent auditor reported effective internal control over financial reporting as of year-end.
Important facts for investors to verify
- Whether revenue growth and improving gross margin continue as the installed base expands, and whether the company can reach sustained profitability.
- Whether manufacturing capacity, yields and supplier availability can support demand without quality or delivery problems.
- Progress on broader reimbursement, particularly Medicare coverage, and the effect of restrictive insurer policies on customer adoption.
- Resolution and follow-up status of the FDA warning letter, and any subsequent regulatory or product-safety developments.
- Revenue and cash-flow exposure to major distributors, continued share-based compensation, and the timing of future capital needs.